PBYI Puma Biotechnology

$3.45 $-0.06 (-1.71%)
Overall

PBYI Stock Analysis Overview

What this means: Puma Biotechnology (PBYI) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Puma Biotechnology above 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

PBYI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

PBYI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

PBYI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

PBYI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

PBYI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

PBYI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

PBYI Stock Analysis Overview

What this means: Puma Biotechnology (PBYI) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Puma Biotechnology above 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full PBYI report

PBYI Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

PBYI Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

PBYI Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

PBYI Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

PBYI Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

PBYI Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Puma Biotechnology (PBYI) Analyst Forecast

PBYI Price, Volume, Earnings, and Dividend Date

  • Last Price $3.45
  • Previous Close $3.51
  • Change $-0.06
  • Open $3.47
  • Volume 153,451
  • Avg. Volume (100-day) 417,836
  • Market Cap 157,168,072
  • Days Range 3.425 - 3.5105
  • 52-week Range 1.6 - 7.84
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS
  • Earnings Date 11/02/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.018
  • PEG Ratio

Puma Biotechnology (PBYI) Company Description

Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.

Puma Biotechnology (PBYI) Stock Chart

My Watchlists

Follow Your Favorite Stocks